Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572251 | 1.00 | MAPT (0.72) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| SCHEMBL7535 | 0.84 | RAB9A (1.00) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL27790630 | 0.82 | RAB9A (0.96) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| SCHEMBL92781 | 0.79 | SMN1; SMN2 (0.61) | MAPTRAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL2190447 | 0.79 | ALDH1A1 (0.61) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| Hydrochloric Acid SCHEMBL11236118 | 0.78 | ALDH1A1 (0.59) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| SCHEMBL9305718 | 0.78 | SMN1; SMN2 (0.53) | MAPTRAB9ASMN1; SMN2TP53ALDH1A1 | |
| Bromide SCHEMBL10996884 | 0.78 | SMN1; SMN2 (0.59) | MAPTRAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL482340 | 0.76 | LOXL2 (0.61) | MAPTRAB9ASMN1; SMN2TP53CYP3A4 | |
| SCHEMBL799569 | 0.76 | SMN1; SMN2 (0.51) | MAPTRAB9ASMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045993-A | Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof | 西南交通大学 | 2021-06-29 | — | — | CN | claimed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| CN-120136812-A | Compound for targeted degradation of transcription factor KLF5 and application thereof | 昆明医科大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025031129-A1 | ARYL UREA DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 沈阳药科大学 | 2025-02-13 | — | — | WO | disclosed |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2024-08-15 | — | — | US | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| CN-117903166-A | Novel ASK1 inhibitor and preparation method and application thereof | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| US-4086241-A | Benzothiazolylimidazolidinone esters of furyl and thienyl substituted acids | VELSICOL CHEMICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4055569-A | HERBICIDE | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054574-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4045446-A | 1-Benzothiazolyl-5-pyridylcarbonyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1977-08-30 | — | — | US | disclosed |
| US-4029491-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
| US-3957752-A | QUATERNIZED AZOANILINO TOLUENE SULFONAMIDOALKYLENE-AMINE DYES | AMERICAN ANILINE PRODUCTS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3950130-A | THIAZOLE-AZO DYES AND THE COLORATION OF POLYESTER TEXTILE FIBERS THEREWITH | AMERICAN ANILINE PRODUCTS, INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | MAPT 4504/4885RAB9A 779/4885SMN1; SMN2 4332/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | MAPT 2434/4885RAB9A 1023/4885SMN1; SMN2 4125/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | MAPT 4819/4885RAB9A 3362/4885SMN1; SMN2 3990/4885 |
| US-20240269304-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | BCL3, BCL9, BCL2L10 | MAPT 3134/4885RAB9A 931/4885SMN1; SMN2 4217/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | MAPT 3674/4885RAB9A 1518/4885SMN1; SMN2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.